Q-omics provides the consensus-scored ANKRD26P4 profile across patient tissues and cancer cell-line models. ANKRD26P4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKRD26P4 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, ANKRD26P4 RNA expression shows 15,905 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ANKRD26P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD26P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD26P4 survival associations across molecular data types. ANKRD26P4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD26P4 RNA expression–survival associations across cancer types. High ANKRD26P4 expression shows unfavorable associations in LIHC, LGG and BLCA, but favorable associations in KIRC, BRCA and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKRD26P4 RNA expression.
This table summarizes ANKRD26P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD26P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD26P4 shows lower tumor expression in THCA, UCEC and KIRP and higher tumor expression in HNSC, ESCA and CHOL. The THCA box plot shows higher ANKRD26P4 RNA expression in normal versus tumor tissue (log2 FC = −0.123, t-test p = .003).
This table shows molecular features associated with ANKRD26P4 in patient tissues and cancer cell lines. In patient samples, ANKRD26P4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
